Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for EXEL

Stock NameExelixis Inc
TickerEXEL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS30161Q1040

Show aggregate EXEL holdings

News associated with EXEL

Exelixis (NASDAQ:EXEL) Price Target Raised to $50.00 at Morgan Stanley
Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective lifted by investment analysts at Morgan Stanley from $46.00 to $50.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 23.61% from the company’s […] - 2025-09-19 02:36:46
Exelixis (NASDAQ:EXEL) Rating Increased to Hold at Barclays
Barclays upgraded shares of Exelixis (NASDAQ:EXEL – Free Report) to a hold rating in a research report report published on Tuesday morning,Zacks.com reports. A number of other analysts also recently weighed in on the company. Bank of America lifted their price target on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating […] - 2025-09-19 02:02:49
Exelixis (NASDAQ:EXEL) Rating Lowered to “Hold” at Wall Street Zen
Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday. Several other equities analysts have also recently issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Exelixis in a […] - 2025-09-15 02:06:56
Zacks Research Predicts Exelixis’ Q3 Earnings (NASDAQ:EXEL)
Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Research analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Exelixis in a research report issued on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.62 per share for the quarter, down from their previous estimate of […] - 2025-09-01 02:44:58
Exelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of “Moderate Buy” from Analysts
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and thirteen have assigned a buy recommendation to the […] - 2025-08-18 05:10:57
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by LPL Financial LLC
LPL Financial LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 74.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,097 shares of the biotechnology company’s stock after purchasing an additional 79,885 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-11 05:34:56
Exelixis, Inc. (NASDAQ:EXEL) Position Increased by Natixis Advisors LLC
Natixis Advisors LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 14.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,922 shares of the biotechnology company’s stock after purchasing an additional 9,072 shares during the period. […] - 2025-08-08 05:18:54
Wall Street Zen Downgrades Exelixis (NASDAQ:EXEL) to Buy
Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Several other equities analysts also recently commented on the stock. HC Wainwright upped their price target on shares of Exelixis from $47.00 to $53.00 […] - 2025-08-04 04:27:00
Exelixis (NASDAQ:EXEL) Given “Market Outperform” Rating at JMP Securities
Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock. JMP Securities’ price objective would suggest a potential upside of 35.69% […] - 2025-07-31 04:18:47
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Truist Financial Has Lowered Expectations for Exelixis (NASDAQ:EXEL) Stock Price
Exelixis (NASDAQ:EXEL – Free Report) had its price objective trimmed by Truist Financial from $56.00 to $49.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also recently weighed in on EXEL. Benchmark reiterated a “neutral” rating […] - 2025-07-30 06:13:05
Exelixis (NASDAQ:EXEL) Given “Outperform” Rating at William Blair
William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on Tuesday morning,RTT News reports. Several other analysts also recently commented on EXEL. Wells Fargo & Company reiterated a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Jefferies Financial […] - 2025-07-30 04:54:52
Exelixis (NASDAQ:EXEL) Given New $45.00 Price Target at Royal Bank Of Canada
Exelixis (NASDAQ:EXEL – Free Report) had its target price cut by Royal Bank Of Canada from $50.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock. EXEL has been the subject of several other research reports. Truist Financial boosted their target […] - 2025-07-30 04:54:49
Morgan Stanley Cuts Exelixis (NASDAQ:EXEL) Price Target to $46.00
Exelixis (NASDAQ:EXEL – Free Report) had its target price decreased by Morgan Stanley from $48.00 to $46.00 in a report released on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. EXEL has been the subject of several other reports. Stephens upgraded Exelixis from an “equal weight” rating to […] - 2025-07-30 04:20:59
Exelixis Target of Unusually Large Options Trading (NASDAQ:EXEL)
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 12,250 call options on the stock. This is an increase of 373% compared to the typical volume of 2,588 call options. Wall Street Analysts Forecast Growth Several brokerages have issued reports on EXEL. Morgan […] - 2025-07-30 03:07:01
Exelixis (NASDAQ:EXEL) Shares Gap Down on Analyst Downgrade
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s share price gapped down before the market opened on Tuesday after Truist Financial lowered their price target on the stock from $56.00 to $49.00. The stock had previously closed at $44.39, but opened at $38.26. Truist Financial currently has a buy rating on the stock. Exelixis shares last […] - 2025-07-30 03:06:57
Arizona State Retirement System Sells 790 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Arizona State Retirement System trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,696 shares of the biotechnology company’s stock after selling 790 shares during the period. Arizona […] - 2025-07-17 06:56:52
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Cerity Partners LLC
Cerity Partners LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 127.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,915 shares of the biotechnology company’s stock after purchasing an additional 94,031 shares during the quarter. Cerity Partners LLC owned […] - 2025-07-16 06:51:24
Exelixis, Inc. (NASDAQ:EXEL) Holdings Reduced by Alps Advisors Inc.
Alps Advisors Inc. decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,709 shares of the biotechnology company’s stock after selling 3,291 shares during the period. Alps Advisors Inc.’s holdings […] - 2025-07-16 05:23:13
Bank of New York Mellon Corp Grows Position in Exelixis, Inc. (NASDAQ:EXEL)
Bank of New York Mellon Corp lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,476,857 shares of the biotechnology company’s stock after purchasing an additional 15,239 shares during the quarter. Bank […] - 2025-07-11 06:13:00
Principal Financial Group Inc. Sells 14,218 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 648,218 shares of the biotechnology company’s stock after selling 14,218 shares during the period. Principal Financial Group Inc. owned approximately 0.24% […] - 2025-07-09 05:51:35
Traders Buy Large Volume of Call Options on Exelixis (NASDAQ:EXEL)
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders purchased 3,495 call options on the stock. This is an increase of 56% compared to the typical daily volume of 2,238 call options. Insider Activity In other Exelixis news, Director Sue Gail Eckhardt sold 18,838 shares […] - 2025-07-09 02:50:45
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York State Teachers Retirement System
New York State Teachers Retirement System cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 12.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 359,105 shares of the biotechnology company’s stock after selling 52,707 shares during the period. New York State Teachers Retirement […] - 2025-07-04 05:31:06
HC Wainwright Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock
Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective hoisted by research analysts at HC Wainwright from $47.00 to $53.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 21.50% from […] - 2025-07-02 03:02:56
Bartlett & CO. Wealth Management LLC Makes New $37,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)
Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,000 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge […] - 2025-06-30 06:44:51
Exelixis (NASDAQ:EXEL) Raised to “Overweight” at Stephens
Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday, Marketbeat Ratings reports. The firm presently has a $60.00 target price on the biotechnology company’s stock, up from their prior target price of $29.00. Stephens’ price […] - 2025-06-26 02:48:49
Exelixis (NASDAQ:EXEL) Shares Gap Up on Analyst Upgrade
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price gapped up prior to trading on Monday after Stephens upgraded the stock from an equal weight rating to an overweight rating. The stock had previously closed at $40.37, but opened at $49.43. Stephens now has a $60.00 price target on the stock, up from their previous […] - 2025-06-25 02:18:52
Exelixis (NASDAQ:EXEL) Reaches New 52-Week High After Analyst Upgrade
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) reached a new 52-week high during trading on Tuesday after Stephens upgraded the stock from an equal weight rating to an overweight rating. Stephens now has a $60.00 price target on the stock, up from their previous price target of $29.00. Exelixis traded as high as […] - 2025-06-25 02:18:49
Blue Trust Inc. Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Blue Trust Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,976 shares of the biotechnology company’s stock after purchasing an additional 1,745 shares during the period. […] - 2025-06-22 05:22:52
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Farther Finance Advisors LLC
Farther Finance Advisors LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 6.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,372 shares of the biotechnology company’s stock after acquiring an additional 307 shares during the quarter. Farther Finance Advisors […] - 2025-06-20 04:26:51

iShares Healthcare Innovation UCITS ETF USD (Acc) EXEL holdings

DateNumber of EXEL Shares HeldBase Market Value of EXEL SharesLocal Market Value of EXEL SharesChange in EXEL Shares HeldChange in EXEL Base ValueCurrent Price per EXEL Share HeldPrevious Price per EXEL Share Held
2025-11-12 (Wednesday)332,328USD 14,486,178USD 14,486,178
2025-11-11 (Tuesday)332,328USD 14,281,796EXEL holding increased by 520094USD 14,281,7960USD 520,094 USD 42.975 USD 41.41
2025-11-10 (Monday)332,328USD 13,761,702EXEL holding increased by 199396USD 13,761,7020USD 199,396 USD 41.41 USD 40.81
2025-11-07 (Friday)332,328USD 13,562,306EXEL holding increased by 3324USD 13,562,3060USD 3,324 USD 40.81 USD 40.8
2025-11-06 (Thursday)332,328USD 13,558,982EXEL holding increased by 142901USD 13,558,9820USD 142,901 USD 40.8 USD 40.37
2025-11-05 (Wednesday)332,328USD 13,416,081EXEL holding increased by 820850USD 13,416,0810USD 820,850 USD 40.37 USD 37.9
2025-11-04 (Tuesday)332,328USD 12,595,231EXEL holding decreased by -53173USD 12,595,2310USD -53,173 USD 37.9 USD 38.06
2025-11-03 (Monday)332,328USD 12,648,404EXEL holding decreased by -202720USD 12,648,4040USD -202,720 USD 38.06 USD 38.67
2025-10-31 (Friday)332,328USD 12,851,124EXEL holding decreased by -89728USD 12,851,1240USD -89,728 USD 38.67 USD 38.94
2025-10-30 (Thursday)332,328USD 12,940,852EXEL holding decreased by -162841USD 12,940,8520USD -162,841 USD 38.94 USD 39.43
2025-10-29 (Wednesday)332,328USD 13,103,693EXEL holding decreased by -214352USD 13,103,6930USD -214,352 USD 39.43 USD 40.075
2025-10-28 (Tuesday)332,328USD 13,318,045EXEL holding increased by 28248USD 13,318,0450USD 28,248 USD 40.075 USD 39.99
2025-10-27 (Monday)332,328USD 13,289,797EXEL holding increased by 422057USD 13,289,7970USD 422,057 USD 39.99 USD 38.72
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of EXEL by Blackrock for IE00BYZK4776

Show aggregate share trades of EXEL

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-2,81838.72039.150 39.107USD -110,204 37.90 Loss of -3,394 on sale
2025-09-11BUY1,41039.07039.090 39.088USD 55,114 37.74
2025-07-08SELL-1,40943.51044.350 44.266USD -62,371 37.33 Loss of -9,775 on sale
2025-06-24SELL-1,40345.72046.140 46.098USD -64,675 36.86 Loss of -12,959 on sale
2025-06-23BUY37243.37049.620 48.995USD 18,226 36.81
2025-06-20SELL-42,14140.37041.030 40.964USD -1,726,264 36.79 Loss of -175,970 on sale
2025-06-11SELL-1,57641.43042.650 42.528USD -67,024 36.54 Loss of -9,432 on sale
2025-05-30SELL-1,57643.04043.130 43.121USD -67,959 36.14 Loss of -11,004 on sale
2025-05-21BUY1,57643.72044.500 44.422USD 70,009 35.73
2025-05-15SELL-9,45646.26048.850 48.591USD -459,476 35.48 Loss of -123,942 on sale
2025-04-30SELL-1,57539.15039.350 39.330USD -61,945 35.17 Loss of -6,558 on sale
2025-04-28SELL-1,57538.44038.570 38.557USD -60,727 35.10 Loss of -5,446 on sale
2025-04-25SELL-1,57537.43037.500 37.493USD -59,051 35.08 Loss of -3,808 on sale
2025-04-11SELL-9,46235.31035.460 35.445USD -335,381 34.96 Loss of -4,577 on sale
2025-04-08SELL-4,73134.13035.860 35.687USD -168,835 34.97 Loss of -3,382 on sale
2025-04-07BUY4,49534.84035.250 35.209USD 158,264 34.97
2025-03-31SELL-3,09436.92037.120 37.100USD -114,787 34.91 Loss of -6,768 on sale
2025-03-21SELL-3,09436.96037.990 37.887USD -117,222 34.74 Loss of -9,751 on sale
2025-03-12SELL-1,54937.20037.320 37.308USD -57,790 34.52 Loss of -4,325 on sale
2025-02-28SELL-1,54938.69038.720 38.717USD -59,973 34.01 Loss of -7,292 on sale
2025-02-25BUY1,54936.92037.570 37.505USD 58,095 33.84
2025-02-20SELL-1,54935.09035.170 35.162USD -54,466 33.70 Loss of -2,268 on sale
2025-02-19BUY3,09835.07035.460 35.421USD 109,734 33.67
2025-02-18BUY1,54934.20035.370 35.253USD 54,607 33.66
2024-12-30BUY3,75133.70034.150 34.105USD 127,928 33.80
2024-12-06SELL-1,52135.82036.150 36.117USD -54,934 33.64 Loss of -3,774 on sale
2024-12-04SELL-1,52135.77035.830 35.824USD -54,488 33.47 Loss of -3,574 on sale
2024-12-03SELL-3,04235.26035.620 35.584USD -108,247 33.41 Loss of -6,620 on sale
2024-11-22BUY2,40135.61035.690 35.682USD 85,672 32.48
2024-11-21SELL-1,51534.83035.000 34.983USD -52,999 32.36 Loss of -3,975 on sale
2024-11-20SELL-1,51934.65034.810 34.794USD -52,852 32.23 Loss of -3,891 on sale
2024-11-19SELL-1,51934.41034.590 34.572USD -52,515 32.10 Loss of -3,749 on sale
2024-11-18SELL-6,05234.52034.630 34.619USD -209,514 31.95 Loss of -16,134 on sale
2024-11-12SELL-1,51335.85036.490 36.426USD -55,113 31.69 Loss of -7,161 on sale
2024-11-07SELL-1,51235.80036.170 36.133USD -54,633 31.03 Loss of -7,720 on sale
2024-11-05SELL-3,02434.77035.150 35.112USD -106,179 30.28 Loss of -14,615 on sale
2024-10-28SELL-1,51328.50028.570 28.563USD -43,216 28.36 Loss of -310 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of EXEL

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19349,3840595,25358.7%
2025-09-18430,45011,761708,16760.8%
2025-09-17504,0831,036836,32160.3%
2025-09-16404,4300563,87571.7%
2025-09-15329,606441529,06562.3%
2025-09-12524,8424,207913,69257.4%
2025-09-11562,1773,134902,87162.3%
2025-09-10572,5673,800905,18463.3%
2025-09-09397,8598,844684,47158.1%
2025-09-08313,70225519,02260.4%
2025-09-05559,0141,313808,21769.2%
2025-09-04422,9076,992675,24762.6%
2025-09-03599,3622,2451,023,15158.6%
2025-09-021,012,2499541,595,65063.4%
2025-08-29501,4432,883758,57366.1%
2025-08-28476,1241,667704,82667.6%
2025-08-27441,436666588,51775.0%
2025-08-26399,8931,239562,75771.1%
2025-08-25355,64431551,40964.5%
2025-08-22308,605540468,55165.9%
2025-08-21589,9020745,82879.1%
2025-08-20385,633314503,58576.6%
2025-08-19433,048813690,89962.7%
2025-08-18468,009321691,08167.7%
2025-08-15387,49929,516649,33659.7%
2025-08-14510,428160775,52265.8%
2025-08-13508,860520720,58870.6%
2025-08-12564,759583792,78271.2%
2025-08-11531,570150830,83864.0%
2025-08-08501,446198911,58055.0%
2025-08-07716,3461291,140,87762.8%
2025-08-06568,916378881,70064.5%
2025-08-05682,74515,4461,418,12848.1%
2025-08-04976,230241,600,05961.0%
2025-08-011,884,4901172,637,56371.4%
2025-07-311,209,0242,2151,711,14770.7%
2025-07-30912,07137,2671,899,82748.0%
2025-07-294,273,219106,2967,518,51856.8%
2025-07-281,728,1198752,115,60781.7%
2025-07-25843,1854011,143,92273.7%
2025-07-24436,484322684,87363.7%
2025-07-23587,5741,065808,71672.7%
2025-07-22495,903110758,13265.4%
2025-07-21417,8490569,34973.4%
2025-07-18376,4451509,08873.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.